US Broker Ratings

West Pharmaceutical Services, I (WST) Stock Analysis: Unpacking a 32% Upside Potential

For investors eyeing opportunities in the healthcare sector, West Pharmaceutical Services, Inc. (NYSE: WST) presents a compelling case. With a robust market cap of $17.2 billion and an influential presence..

Gilead Sciences, Inc. (GILD) Stock Analysis: Navigating Growth Amidst a Challenging Market Environment

Gilead Sciences, Inc. (NASDAQ: GILD), a stalwart in the biopharmaceutical space, continues to captivate investor attention with its robust product portfolio and strategic collaborations. With a market capitalization of $140.79..

Molina Healthcare Inc (MOH) Stock Analysis: Assessing a Compelling 30% Upside Potential

Molina Healthcare Inc (NYSE: MOH) is a prominent player in the healthcare sector, specifically within the healthcare plans industry. This Long Beach, California-based company focuses on providing managed healthcare services..

Chemed Corp (CHE) Investor Outlook: Analyzing a 35.75% Potential Upside with Robust Free Cash Flow

Chemed Corp (NYSE: CHE), a major player in the healthcare sector, operates through its two main segments, VITAS and Roto-Rooter. Known for its hospice and palliative care services, Chemed is..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Balancing Potential Upside with Strategic R&D Investments

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a powerhouse within the biotechnology sphere, recognized for its groundbreaking therapies in treating cystic fibrosis (CF). With a market capitalization of $118.67 billion,..

Royalty Pharma plc (RPRX) Stock Analysis: A Healthcare Giant with 13.58% Potential Upside

Royalty Pharma plc (NASDAQ: RPRX), a formidable player in the biotechnology sector, is drawing investor attention with its robust market presence and promising growth potential. With a current market capitalization..

Neurocrine Biosciences, Inc. (NBIX) Rating Update: Exploring a 30% Potential Upside

Neurocrine Biosciences, Inc. (NBIX) is drawing considerable attention in the healthcare sector, particularly among investors focused on drug manufacturers specializing in both specialty and generic products. With a market capitalization..

Viatris Inc. (VTRS) Stock Analysis: Exploring the 26.48% Potential Upside Amidst Financial Challenges

Viatris Inc. (NASDAQ: VTRS), a prominent player in the healthcare sector specializing in both specialty and generic drug manufacturing, presents a curious case for investors. Despite facing significant financial headwinds,..

Labcorp Holdings Inc. (LH) Stock Analysis: Unlocking 11.53% Potential Upside with Strong Buy Ratings

Labcorp Holdings Inc. (NYSE: LH) is a leading player in the healthcare sector, specifically in the diagnostics and research industry. Headquartered in Burlington, North Carolina, Labcorp provides a comprehensive range..

Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield

Bristol-Myers Squibb Company (NYSE: BMY), a stalwart in the healthcare sector and a prominent player in the global biopharmaceutical arena, presents an intriguing investment case. With a market capitalization of..

Merck & Company, Inc. (MRK) Stock Analysis: High Dividend Yield and a 26.64% Potential Upside

Merck & Company, Inc. (NYSE: MRK) stands as a formidable player in the healthcare sector, renowned for its extensive portfolio of pharmaceuticals and animal health products. As a major entity..

Masimo Corporation (MASI) Stock Analysis: Uncovering Growth Potential with a 19.8% Upside

Masimo Corporation (MASI), a prominent player in the medical devices sector, offers a compelling investment case with a potential upside of 19.8%, according to recent analyst ratings. Headquartered in Irvine,..

Dr. Reddy’s Laboratories Ltd (RDY) Stock Analysis: Navigating a 7.55% Upside Potential in Healthcare

Dr. Reddy’s Laboratories Ltd (NYSE: RDY), a prominent player in the healthcare sector, particularly in the specialty and generic drug manufacturing industry, commands a significant presence across North America, Europe,..

Insmed Incorporated (INSM) Investor Outlook: Strong Buy Ratings and Promising Pipeline Propel Growth Potential

Insmed Incorporated (NASDAQ: INSM), a prominent player in the biotechnology sector, is catching the attention of investors with its robust growth trajectory and promising clinical pipeline. Headquartered in Bridgewater, New..

Genmab A/S (GMAB) Stock Analysis: Biotechnology Leader with a 41% Potential Upside

Genmab A/S, trading under the symbol GMAB, is a prominent player in the biotechnology sector with a formidable market capitalization of $13.4 billion. Based in Denmark, the company has carved..

Universal Health Services, Inc. (UHS) Stock Analysis: Exploring a Potential 36.63% Upside

Universal Health Services, Inc. (NYSE: UHS) stands as a formidable player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $10.5 billion, the..

Align Technology, Inc. (ALGN) Stock Analysis: Unveiling a 36.51% Potential Upside

Align Technology, Inc. (NASDAQ: ALGN), a titan in the healthcare sector specializing in medical instruments and supplies, has long been a staple for investors looking to capitalize on the burgeoning..

Exact Sciences Corporation (EXAS) Stock Analysis: Is a 43% Upside Within Reach?

Investors looking to capitalize on the healthcare sector’s growth potential might find Exact Sciences Corporation (NASDAQ: EXAS) an intriguing prospect. With a market capitalization of $9.01 billion, this diagnostics and..

Quest Diagnostics (DGX) Stock Analysis: Exploring a 10% Potential Upside for Savvy Investors

Quest Diagnostics Incorporated (NYSE: DGX), a leader in the healthcare sector, operates within the Diagnostics & Research industry. With a robust market capitalization of $19.1 billion, Quest Diagnostics stands as..

Insulet Corporation (PODD) Stock Analysis: A Robust Healthcare Player with 19% Potential Upside

Insulet Corporation (NASDAQ: PODD) stands tall in the healthcare sector, specializing in medical devices that revolutionize insulin delivery systems. With a market capitalization of $20.05 billion, Insulet is a substantial..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds